Jim Wassil - 03 Feb 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
03 Feb 2025
Net transactions value
-$670,430
Form type
4
Filing time
04 Feb 2025, 19:20:00 UTC
Previous filing
03 Jan 2025
Next filing
03 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $19,360 +8,000 +3.9% $2.42 213,695 03 Feb 2025 Direct
transaction PCVX Common Stock Sale $456,983 -5,314 -2.5% $86.00 208,381 03 Feb 2025 Direct F1, F2
transaction PCVX Common Stock Sale $231,049 -2,666 -1.3% $86.66 205,715 03 Feb 2025 Direct F1, F3
transaction PCVX Common Stock Sale $1,759 -20 -0.01% $87.94 205,695 03 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -8,000 -75% $0.000000 2,638 03 Feb 2025 Common Stock 8,000 $2.42 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $85.32 to $86.295. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $86.365 to $87.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Option is fully vested and exercisable.